Johnson & Johnson aims for initial approval of nipocalimab to treat a wide range of patients with antibody-positive generalized myasthenia gravis.

Merck has recently divulged advancements pertaining to two pivotal Phase 3 clinical trials, designated as KEYNOTE-867 and KEYNOTE-630.

Rallybio Unveils RLYB212's Phase 1 Exploratory Study Outcomes in Blood Clotting & Coagulation Dynamics.

Bayer has disclosed the enrollment of the inaugural patient into the international Phase III SOHO-02 study, a randomized, open-label, multicenter clinical endeavor.

Merck KGaA, headquartered in Darmstadt, Germany, Reveals Initiation of Phase III Trial with Oral Cladribine for Treating Generalized Myasthenia Gravis (gMG), Marking First Patient Administration.

Biocon Biologics Achieves Market Access for Bmab 1200, a Biosimilar Candidate Akin to Stelara®, Across Europe, the UK, Canada, and Japan.

Jeune Aesthetics Reveals Encouraging Interim Safety & Efficacy Outcomes for KB301 in Phase 1, Targeting Lateral Eye Creases & Active Décolletage Wrinkles Reduction.

Neurocrine Biosciences Announces Encouraging Phase 2 Outcomes for NBI-1117568 in Adult Schizophrenia Patients, Demonstrating Potential Efficacy.

Novartis' biannual Leqvio® showed significant and meaningful LDL-C reduction as a solo treatment for patients with low to moderate ASCVD risk.

Merck Begins Phase 3 Study of Bomedemstat, an Experimental Drug for Specific Essential Thrombocythemia Patients.

Cantargia (Cantargia AB, Nasdaq Stockholm: CANTA) has updated the anticipated schedules for nadunolimab clinical studies.

Centessa Pharmaceuticals Unveils Late-Breaking Poster on Non-Human Primate Data for ORX142, a New Orexin Receptor 2 (OX2R) Agonist.